<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Clin. Invest</journal-id>
<journal-id journal-id-type="publisher-id">J Clin Invest</journal-id>
<journal-title-group>
<journal-title>The Journal of Clinical Investigation</journal-title>
</journal-title-group>
<issn pub-type="ppub">0021-9738</issn>
<issn pub-type="epub">1558-8238</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30106381</article-id>
<article-id pub-id-type="pmc">6205398</article-id>
<article-id pub-id-type="publisher-id">98199</article-id>
<article-id pub-id-type="doi">10.1172/JCI98199</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hacohen-Kleiman</surname>
<given-names>Gal</given-names>
</name>
<email>gal-kl@hotmail.com</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sragovich</surname>
<given-names>Shlomo</given-names>
</name>
<email>srshlomo@gmail.com</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Karmon</surname>
<given-names>Gidon</given-names>
</name>
<email>gidikarmon@gmail.com</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Andy Y. L.</given-names>
</name>
<email>andy.gao@mail.mcgill.ca</email>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grigg</surname>
<given-names>Iris</given-names>
</name>
<email>iris.grigg5@gmail.com</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pasmanik-Chor</surname>
<given-names>Metsada</given-names>
</name>
<email>metsada@post.tau.ac.il</email>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Le</surname>
<given-names>Albert</given-names>
</name>
<email>albert.le@mail.mcgill.ca</email>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Korenková</surname>
<given-names>Vlasta</given-names>
</name>
<email>vlasta.korenkova@ibt.cas.cz</email>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McKinney</surname>
<given-names>R. Anne</given-names>
</name>
<email>anne.mckinney@mcgill.ca</email>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gozes</surname>
<given-names>Illana</given-names>
</name>
<email>igozes@post.tau.ac.il</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>The Lily and Avraham Gildor Chair for the Investigation of Growth Factors; The Elton Laboratory for Neuroendocrinology; Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Sagol School of Neuroscience and Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv, Israel.</aff>
<aff id="A2"><label>2</label>Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.</aff>
<aff id="A3"><label>3</label>Bioinformatics Unit, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.</aff>
<aff id="A4"><label>4</label>BIOCEV, Institute of Biotechnology CAS, Vestec, Czech Republic.</aff>
<author-notes>
<corresp>Address correspondence to: Illana Gozes, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, Head, the Dr. Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel. Phone: 972.3.640.7240; Email: <email>igozes@post.tau.ac.il</email>.</corresp>
<fn>
<p><bold>Authorship note:</bold> GHK and SS contributed equally to this work.</p>
</fn>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest:</bold> IG is the chief scientific officer of Coronis Neurosciences, which is developing NAP (CP201) for <italic>ADNP</italic> syndrome. NAP (CP201) use is under patent protection (US patent nos. US7960334, US8618043, and US7452867; patent publication no. WO2017130190A1.)</p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2018-09-24T16:00:00-0400" publication-format="electronic">
<day>24</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date date-type="collection" iso-8601-date="2018-09-24T16:00:00-0400" publication-format="electronic">
<day>24</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date date-type="pub" iso-8601-date="2018-11-01T16:00:00-0400" publication-format="print">
<day>1</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>2</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 3 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>128</volume>
<issue>11</issue>
<fpage>4956</fpage>
<lpage>4969</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>10</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>7</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018, American Society for Clinical Investigation</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>American Society for Clinical Investigation</copyright-holder>
</permissions>
<self-uri xlink:href="https://www.jci.org/articles/view/98199">This article is available online at https://www.jci.org/articles/view/98199</self-uri>
<abstract>
<p>Previous findings showed that in mice, complete knockout of activity-dependent neuroprotective protein (ADNP) abolishes brain formation, while haploinsufficiency (<italic>Adnp<sup>+/–</sup></italic>) causes cognitive impairments. We hypothesized that mutations in <italic>ADNP</italic> lead to a developmental/autistic syndrome in children. Indeed, recent phenotypic characterization of children harboring <italic>ADNP</italic> mutations (<italic>ADNP</italic> syndrome children) revealed global developmental delays and intellectual disabilities, including speech and motor dysfunctions. Mechanistically, ADNP includes a SIP motif embedded in the ADNP-derived snippet drug candidate NAP (NAPV<underline>SIP</underline>Q, also known as CP201), which binds to microtubule end–binding protein 3, essential for dendritic spine formation. Here, we established a unique neuronal membrane–tagged, GFP-expressing <italic>Adnp<sup>+/–</sup></italic> mouse line allowing in vivo synaptic pathology quantification. We discovered that <italic>Adnp</italic> deficiency reduced dendritic spine density and altered synaptic gene expression, both of which were partly ameliorated by NAP treatment. <italic>Adnp<sup>+/–</sup></italic>mice further exhibited global developmental delays, vocalization impediments, gait and motor dysfunctions, and social and object memory impairments, all of which were partially reversed by daily NAP administration (systemic/nasal). In conclusion, we have connected ADNP-related synaptic pathology to developmental and behavioral outcomes, establishing NAP in vivo target engagement and identifying potential biomarkers. Together, these studies pave a path toward the clinical development of NAP (CP201) for the treatment of <italic>ADNP</italic> syndrome.</p>
</abstract>
<kwd-group kwd-group-type="specialties">
<kwd>Therapeutics</kwd>
</kwd-group>
<kwd-group kwd-group-type="keywords">
<kwd>Drug therapy</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>ERDF, and MEYS CR</funding-source>
<award-id>CAS (RVO: 86652036)</award-id>
<award-id>LQ1604 NPU II,project BIOCEV (CZ.1.05/1.1.00/02.0109)</award-id>
</award-group>
<award-group>
<funding-source>Israel Ministry of Science and Technology</funding-source>
<award-id>Eshkol fellowships</award-id>
</award-group>
<award-group>
<funding-source>Tel Aviv University Global Research &amp; Training Fellowship and The Naomi Foundation and The Eldee Foundation/Bloomfield Family of Montreal</funding-source>
<award-id>awards for student exchange</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Israel Science Foundation</institution>
<institution-id>https://doi.org/10.13039/501100003977</institution-id>
</institution-wrap>
</funding-source>
<award-id>ISF 1424/14</award-id>
</award-group>
<award-group>
<funding-source>ERA-NET Neuron</funding-source>
<award-id>AUTYSM</award-id>
</award-group>
<award-group>
<funding-source>AMN Foundation</funding-source>
<award-id>AMN Foundation</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>CIHR</institution>
<institution-id>https://doi.org/10.13039/501100007202</institution-id>
</institution-wrap>
</funding-source>
<award-id>CIHR</award-id>
</award-group>
<award-group>
<funding-source>Drs. Ronith and Armand Stemmer, Mr Arthur Gerbi (French Friends of Tel Aviv University), and Spanish Friends of Tel Aviv University</funding-source>
<award-id>University Support</award-id>
</award-group>
<funding-statement>G.H.K. and S.S. are supported by Eshkol fellowships, the Israel Ministry of Science and Technology. S.S. is further supported by the Tel Aviv University Global Research &amp; Training Fellowship and The Naomi Foundation, as well as The Eldee Foundation/Bloomfield Family of Montreal awards for student exchange (Tel Aviv University/McGill University). V.K. is supported by the CAS (RVO: 86652036) and LQ1604 NPU II, project BIOCEV (CZ.1.05/1.1.00/02.0109) from the ERDF, and MEYS CR. I. Gozes is supported by the following grants, ISF 1424/14, ERA-NET neuron AUTYSM, AMN Foundation as well as Drs. Ronith and Armand Stemmer, Mr Arthur Gerbi (French Friends of Tel Aviv University), and Spanish Friends of Tel Aviv University. R.A. McKinney is supported by CIHR.</funding-statement>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>